Hello, everyone, and how are you today? A steely gray sky is hovering this morning over the Pharmalot campus, where the official mascot has begun his latest round of hours-long snoozing. As for us, we are foraging for interesting stories and quaffing cups of stimulation, as you might have guessed. Our choice today is a Mardi Gras blend. We will leave it to you to guess what it contains. And how is your morning going? Is your schedule filled with meetings and deadlines and what-not? To help you along, here are some tidbits. Hope you conquer the world, and do keep us in mind when you see something fascinating. …
The European Medicines Agency has not identified any safety signals in the region related to the updated Covid-19 booster shot from Pfizer and BioNTech, Reuters notes. Last Friday, the U.S. Food and Drug Administration and the U.S. Centers for Disease Control and Prevention said that a safety monitoring system had flagged that the shot could possibly be linked to a type of brain stroke in older adults, according to preliminary data. In their own statement, the companies acknowledged that they were aware of limited reports of ischemic strokes in people 65 and older following vaccination with their updated booster.
The World Health Organization announced plans to create a TB Vaccine Accelerator Council to increase momentum for developing a vaccine to combat the world’s most deadly infectious disease, Health Policy Watch writes. The new council will include global agencies and governments, funders, and people who have the disease. A United Nations High-Level Meeting on TB is planned for the week of the UN General Assembly in September to review progress against commitments made in the 2018 UN political declaration on ending TB. A recent WHO study found a vaccine with just 75% efficacy could prevent 110 million new cases and 12.3 million deaths over 25 years.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect